RxDoctor Payments Data

Stephen Minton, MD

Internal Medicine · Alexandria, VANPI 1447214150

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 21 payments — averaging $51.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$596
  • AbbVie$232
  • Eisai Inc.$85
  • Pfizer$60
  • Novo Nordisk$49
  • Abbott$30
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$596
AbbVie9$232
Eisai Inc.1$85
Pfizer3$60
Novo Nordisk3$49
Abbott2$30
GSK1$17
Amarin Pharma, Inc.1$16

How this compares

$1,085 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$173,855
Medicare patients
272
Services billed
2,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$90,681
OzempicSemaglutide34$46,192
XareltoRivaroxaban36$40,906
JardianceEmpagliflozin26$28,466
JanumetSitagliptin Phos/Metformin Hcl16$13,433
SynthroidLevothyroxine Sodium64$4,313
Atorvastatin Calcium328$4,045
AliskirenAliskiren Hemifumarate11$3,381
Metoprolol Succinate137$3,090
Levothyroxine Sodium133$3,003
Risedronate Sodium DrRisedronate Sodium14$2,768
Tamsulosin Hcl100$2,502
Rosuvastatin Calcium145$2,374
Fesoterodine Fumarate ErFesoterodine Fumarate18$1,979
Ezetimibe25$1,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$90,681101 claims
Novo NordiskOzempic$49$46,19234 claims
AbbVieSynthroid$232$4,31364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →